5677-54-3

Upstream product

• 13190-97-1 solanesol 
• 3066-90-8 2,3-dimethoxy-5-methylbenzene-1,4-diol 
• 303-97-9 ubiquinone-45 
• 303-98-0 ubidecarenone 
• 2394-68-5 ubiquinone 8 
• 303-95-7 Ubichinon-7 
• 52610-77-2 solanesyl bromide 
• 83626-22-6 2,3-Dimethoxy-6-methyl-4-((2E,6E,10E,14E,18E,22E,26E,30E)-3,7,11,15,19,23,27,31,35-nonamethyl-hexatriaconta-2,6,10,14,18,22,26,30,34-nonaenyloxy)-phenol 

Downstream Products

• 303-97-9 ubiquinone-45 

Relevant academic research and scientific papers

PROCESS FOR THE PREPARATION OF UBIHYDROQUINONES AND UBIQUINONES

A process for the preparation of ubihydroquinones and ubiquinones by condensation of a prenol or isoprenol with a hydroquinone or derivative thereof in the presence of 0.005 - 1.0 mol% of a catalyst which is a Broensted-acid, a Lewis-acid from the group consisting of a derivative of Bi or In or an element of group 3 of the periodic table of the elements, a heteropolyacid, an NH- or a CH-acidic compound, and optionally oxidizing the ubihydroquinone obtained.

METHOD OF PRODUCING REDUCED COENZYME Q10 USING SOLVENT WITH HIGH OXIDATION-PROTECTIVE EFFECT

The present invention relates to a method of conveniently and efficiently producing reduced coenzyme Q10 having excellent qualities which is useful in foods, functional nutritive foods, specific health foods, nutritional supplements, nutrients, drinks, feeds, animal drugs, cosmetics, medicines, remedies, preventive drugs, etc. This method is suitable for industrial production thereof. In a method of synthesizing reduced coenzyme Q10 by reducing oxidized coenzyme Q10, followed by crystallization, at least one species selected from among hydrocarbons, fatty acid esters, ethers and nitriles is used as a solvent. Thus, the reduced coenzyme Q10 can be protected from oxidation, and as a result, the formation of the oxidized coenzyme Q10 as a by-product can be minimized, thereby giving reduced coenzyme Q10 having excellent qualities.

METHOD OF PRODUCING REDUCED COENZYME Q10 CRYSTALS WITH EXCELLENT HANDLING PROPERTIES

The present invention provides a method of producing reduced coenzyme Q10 crystals suitable for commercial scale production thereof. According to a method of the present invention of producing a reduced coenzyme Q10 crystal which comprises a crystallization of reduced coenzyme Q10 in a solution of alcohols and/or ketones, reduced coenzyme Q10 crystal excellent in slurry properties and crystalline properties maybe obtained. Moreover, an isolation process including a crystal separation or the whole process including the isolation process may be minimized and simplified. Thus, highly pure reduced coenzyme Q10 may be obtained in a high yield.

METHOD OF STABILIZING REDUCED COENZYME Q10 AND METHOD OF ACIDIC CRYSTALLIZATION

The present invention relates to a method of efficiently producing reduced coenzyme Q10 having excellent qualities which is useful as an ingredient in foods, functional nutritive foods, specific health foods, nutritional supplements, nutrients, animal drugs, drinks, feeds, cosmetics, medicines, remedies, preventive drugs, etc. This method is suitable for industrial production thereof. It is possible to handle reduced coenzyme Q10 in state of being protected from oxidation by molecular oxygen by bringing the reduced coenzyme Q10 in contact with a solvent containing a strong acid. Furthermore, when reduced coenzyme Q10 is crystallized in the presence of a strong acid, crystallization can be carried out while the formation of oxidized coenzyme Q10 as a by product is minimized, and, then high-quality crystals thereof can be produced.

REGIOSELECTIVE POLYPRENYL REARRANGEMENT OF POLYPRENYL 2,3,4,5-TETRASUBSTITUTED PHENYL ETHERS PROMOTED BY BORON TRIFLUORIDE

4-Acetoxy-6-polyprenyl-2,3,5-trimethylphenols or 2,3-dimethoxy-5-methyl-6-polyprenylhydroquinones were obtained selectively by the BF3*OEt2 catalyzed polyprenyl rearrangement of polyprenyl 4-acetoxy-2,3,5-trimethylphenyl ethers or polyprenyl 2,3-dimethoxy-4-hydroxy-5-methylphenyl ethers.